Background:

Atherosclerosis is characterized by the deposition of cholesterol and hardening of the endothelium. Evolocumab is a monoclonal antibody that inhibits PCSK9 and stabilizes the atheromatous plaque.

Objective:

To evaluate the effect of evolocumab and statins on peripheral arterial disease (PAD).

Methods:

A prospective observational cohort study that included 303 patients with PAD in claudication treated with statins and evolocumab and evolocumab, compared to monotherapy with statins, during a period of six months, from July 2021 to July 2022. Baseline and final measurements of serum LDL levels, the percentage of arterial stenosis by arterial Doppler ultrasound, the ankle-brachial index and claudication were obtained. Kruskal-Wallis and Mann-Whitney U tests were performed.

Results:

The combined treatment reduced the percentage of arterial stenosis in the femoral, tibial, and peroneal branches (p < 0.05) as well as in LDL levels (p < 0.0001) and reported 50% less claudication.

Conclusions:

In our study, the treatment with evolocumab and statins decreased arterial stenosis and claudication in patients with PAD.

        · resumen en Español     · texto en Español     · Español ( pdf )